iLite IL-23 Assay Ready Cells

$1,240.00

The Eagle Biosciences iLite IL-23 Assay Ready Cells are designed for the specific detection of drug potency in serum/plasma as well as neutralizing antibodies. They utilize an assay technique called reporter gene assay ( RPG ) to analyze serum/plasma samples. The reporter genes utilized are encoded with a bioluminescent luciferase (Firefly luciferase). Different levels of luminescence detected from each reporter gene cell indicates levels of expression. The iLite IL-23 Assay Ready Cells are for research use only and not for use in therapeutic procedures.

iLite IL-23 Assay Ready Cells

For Research Use Only

The Eagle Biosciences iLite® IL-23 Assay Ready Cells are intended for:

    • Testing IL-23 or p40 inhibitor activity
    • Testing NAb against IL-23 activity

    Content: >250 µL of Assay Ready Cells suspended in RPMI 1640 medium with 20% heat inactivated fetal bovine serum (FBS) and 10% dimethyl sulfoxide (DMSO).

    Storage: -80°C, Cells should be used within 30 min of thawing.


    Key benefits of iLite® Assays

    • Highly specific reporter gene cell lines
    • Very sensitive cell line responses (>10 fold inductions)
    • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
    • Assays within a workday (typically 4-7 hour assays)
    • Normalization gene, which eliminates unwanted matrix effects

    Product Developed and Manufactured by Svar Life Science

Additional Information

Background

Interleukin 23 (IL-23) is a heterodimeric pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. IL-23 has been implicated as an inflammation mediator in several autoimmune diseases, and has also been found to promote tumor growth. Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders.

Assay Principle

Interleukin 23 (IL-23) is a heterodimeric pro-inflammatory cytokine that shares traits with IL-12. Both cytokines contain the p40 subunit which binds to the receptor chain IL-12Rβ1. However, the two cytokines exert distinct non-redundant biological functions. IL-23 has been implicated as an inflammation mediator in several autoimmune diseases, and has also been found to promote tumor growth. Therapeutic agents targeting both IL-12 and IL-23 cytokines are currently used to treat psoriasis and psoriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders.

Assay Quick Guide

Click here for the Assay Summary: IL-23 Activity Protocol

Why Choose the iLite® IL-23 Assay Ready Cells?

  • iLite technology employs the cells’ inherent signaling pathways – a true model of cellular events
  • Assay Ready Cells – no culturing required!
  • No protein tagging or labeling required
  • Short assay times
  • IL-23 inhibitor activity: 30min + 5h
  • Neutralizing antibodies: 30min + 30 min + 5h
  • Highly reproducible between batches
  • Normalization gene allows for consistent results
  • Adjusts for serum matrix effects and differences in cell number
  • Highly specific for IL-23, no cross-talk with IL-12

Frequently Asked Questions


Manual

Product Manual


Publications

References